Can I read A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in The UK - PubMed on EtoBox?

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in The UK - PubMed by kr4rmy6fsh is a document available to read on EtoBox.

What is A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in The UK - PubMed about?

This study evaluates the cost-effectiveness of once-weekly semaglutide compared to other GLP-1 receptor agonists in treating type 2 diabetes in the UK. Results indicate that semaglutide is more effective in achieving HbA1c and weight loss targets, offering superior efficacy-to-cost ratios. Therefore, semaglutide represents good value for money in the UK healthcare setting.

Author

kr4rmy6fsh

Language

EN